About TBIO
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system, that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an i... [Read more]
Industry Medical Devices
Sector Healthcare
IPO Date Jun 18, 2021
Employees 137
Stock Exchange NASDAQ
Ticker Symbol TBIO
Full Company Profile
Financial Performance
In 2023, Telesis Bio's revenue was $27.51 million, an increase of 0.27% compared to the previous year's $27.44 million. Losses were -$49.02 million, 1.14% more than in 2022.
Financial Statements
News
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated benchtop DNA and mRNA synthesis solutions, today announced a focus in strategy enabled by the comme...
16 hours ago - GlobeNewsWire
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fl...
21 days ago - GlobeNewsWire
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, fle...
7 weeks ago - GlobeNewsWire
Telesis Bio Reports Third Quarter 2023 Financial Results
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter o...
5 months ago - GlobeNewsWire
Telesis Bio to Report Third Quarter Financial Results on Monday, November 13, 2023
SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 ...
5 months ago - GlobeNewsWire
Telesis Bio Announces Commercial Release of Cell-free Amplification Kit for Generation of Transfection-scale DNA
New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days New Kit offers BioXp automation workflow from candidate sequence to amplified DNA in days
5 months ago - GlobeNewsWire
Telesis Bio Announces Commercial Release of BioXp® NGS Library Prep Kit for WGS
New Kit expands suite of NGS Library Prep solutions on the BioXp® System Enabling Speed and Efficiency for Whole genome sequencing (WGS) applications with the Automated Molecular Biology Workstation N...
7 months ago - GlobeNewsWire
Telesis Bio Appoints William J. Kullback Chief Financial Officer
SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Off...
8 months ago - GlobeNewsWire
Telesis Bio Reports Second Quarter 2023 Financial Results
-- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year -- Total revenue of $8.7M in 2QFY23 - increased by 53% year over year
9 months ago - GlobeNewsWire
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio(Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 ...
9 months ago - GlobeNewsWire
Telesis Bio to Present at Jefferies Healthcare Conference 2023
SAN DIEGO, June 08, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, announced that Todd R. Nelson, Ph.D., CEO and Founder of...
11 months ago - GlobeNewsWire
Telesis Bio to Present at Antibody Engineering and Therapeutics, Europe 2023
Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery Showcasing full suite of molecular biology workflow solutions for streamlining antibody discovery
11 months ago - GlobeNewsWire
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock
SAN DIEGO, June 05, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced the ...
11 months ago - GlobeNewsWire
Telesis Bio Secures Financing of $28.0 Million
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC with participation from Northpond Ventures, M-185 Corporation and BroadOak Capital Partners SAN DIE...
11 months ago - GlobeNewsWire
Telesis Bio to Present at SynBioBeta 2023
Highlighting application of the Molecular Biology Workstation to accelerating vaccine and biologics discovery Highlighting application of the Molecular Biology Workstation to accelerating vaccine and ...
11 months ago - GlobeNewsWire
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit
New Kit Enables Automation of DNA Cloning on the BioXp® System Beginning from Linear DNA, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit...
11 months ago - GlobeNewsWire
Telesis Bio Announces First Commercial Shipment of BioXp® NGS Library Prep Kit
New Kit Enables Automation of NGS Library Prep on the BioXp® System Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Molecular Biology Workstation New Kit Enables Automation of...
1 year ago - GlobeNewsWire
Telesis Bio to Present at Protein Engineering Summit (PEGS Boston 2023)
Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications Showcasing Automated Molecular Biology Workstation for Synthetic Biology and Genomics Applications
1 year ago - GlobeNewsWire
Telesis Bio Reports First Quarter 2023 Financial Results
-- Total revenue of $6.3M in 1QFY23 -- BioXp®franchise revenue increased by 28% SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synth...
1 year ago - GlobeNewsWire
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023
SAN DIEGO, April 27, 2023 (GLOBE NEWSWIRE) -- Telesis Bio(Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its first quarter 2023 ...
1 year ago - GlobeNewsWire
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up
New Releases Extend the BioXp® Select Product Line, Further Expanding the Utility, Speed, and Impact of the BioXp® Automated Synthetic Biology Workstation New Releases Extend the BioXp® Select Product...
1 year ago - GlobeNewsWire
Telesis Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Guidance
-- Record revenue of $9.5M in 4QFY22; Increase of 208% over 4QFY21
1 year ago - GlobeNewsWire
Telesis Bio to Present at Festival of Biologics Conference
Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions” Daniel Gibson, Ph.D., CTO and ...
1 year ago - GlobeNewsWire
Telesis Bio to Present at RNA Leaders Europe Congress
Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA Showcasing Benchtop Automation for mRNA Synthesis beginning from Sequence or Plasmid DNA
1 year ago - GlobeNewsWire
Telesis Bio to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 21, 2023
SAN DIEGO, March 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio(Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its fourth quarter and ...
1 year ago - GlobeNewsWire
